Switch to हिंदी

Health, Fitness, Beauty & Diet | Pregnancy & Parenting | Diseases & Home Remedies | TheHealthSite.com

Health, Fitness, Beauty & Diet | Pregnancy & Parenting | Diseases & Home Remedies | TheHealthSite.com

हिंदी
  • Health A-Z
  • Home Remedies
  • Diseases
    • Type 1 Diabetes
    • Type 2 Diabetes
    • Cancer
    • Heart Attack
    • Pneumonia
    • Diseases A-Z
  • Diet & Fitness
    • Weight Management
    • Exercise & Body Building
    • Diet & Recipes
    • Yoga
  • Coronavirus
  • News
  • Pregnancy
    • Conceiving
    • Infertility
    • Labour & Delivery
    • Pregnancy week-by-week
    • Breastfeeding
    • Baby Names
  • Beauty
    • Skin
    • Hair
    • Grooming
  • Photos
  • Videos
BLA21 cibil.com ageas federal zee hindustan
Home / Health News / Oral cancer drug may help combat COVID-19: Clinical trial on

Oral cancer drug may help combat COVID-19: Clinical trial on

US researchers are conducting clinical trials to determine if oral cancer drug ibrutinib can also help patients with immunocompromised conditions recover from COVID-19.

By: Jahnavi Sarma   | | Published: July 31, 2020 2:26 pm
Tags: corona vaccine  Coronavirus  coronavirus outbreak  Medical research  
COVID-19
coronavirus

The COVID-19 virus has spread to all corners of the world in a very short span of time ravaging the economy and claiming lives. The current situation in India too is critical with thousands of cases being reported every day. Precautionary methods like washing hands frequently and social distancing will only work to a certain extent. Without a vaccine, things look bleak. Though scientists are working around the clock to develop a vaccine and cure for this disease, nothing concrete has emerged yet. However, now there are over 200 hopeful candidates, and a few are in final stages of clinical trials. Experts are also looking at existing drugs that have be of help. Also Read - COVID-19 antibodies, vaccines less effective against coronavirus variants: Study

Researchers from Ohio State University Comprehensive Cancer Center (OSUCC) in the US are now conducting a new clinical trial to determine if an oral cancer drug called ibrutinib can also help patients with cancer or other immunocompromised conditions recover from COVID-19. Also Read - Corona passport: Not recommended but may be unavoidable, says WHO



All about this cancer drug

Ibrutinib is an oral therapy in a class of drugs known as Bruton’s tyrosine kinase (BTK) inhibitors. These drugs work by blocking specific chemical reactions in the body involved in cellular processes. According to researchers, Ibrutinib targets and blocks a specific kinase related to lung inflammation. They believe it could have real potential to help decrease this inflammation by shutting down the inappropriate cytokine release that is common in COVID-19–a sort of overreaction from the immune system that can cause many problems, including life-threatening respiratory challenges. Also Read - ‘Get COVID-19 vaccination 24*7’: Government removes time cap

Use of this drug is considered experimental for this study. However, ibrutinib is approved by the US FDA for the treatment of certain cancers, including mantle cell lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma and others.

Trials to start soon

For this phase II clinical trial, the research team will enroll up to 78 patients with cancer or a precancerous condition who have been hospitalised as a result of a Covid-19 infection. According to researchers, the preliminary data suggests ibrutinib has the potential to reduce rates of respiratory failure and death in COVID-19-infected patients. They add that patients will be monitored throughout study treatment with blood work to measure inflammatory markers, immune response and other bodily functions.

Hope for immunocompromised patients

Individuals with cancer or certain precancerous conditions can have lower immunity to diseases and infection, due to treatment or the nature of the disease. Clinical trials are essential to try to improve COVID-19 care in these patients, because a COVID-19 infection can be even more dangerous for those who are immunocompromised.

(With inputs from IANS)

Published : July 31, 2020 2:26 pm
Read Disclaimer

Watch the COVID19 Health Summit on WION

Watch the COVID19 Health Summit on WION

Children below 5 more likely to spread COVID-19 infection, carry very high virus load

Children below 5 more likely to spread COVID-19 infection, carry very high virus load

Please Wait. Article Loading ....

Coronavirus Updates

Coronavirus Updates

Stay Informed, Be Safe

  • COVID-19 antibodies, vaccines less effective against coronavirus variants: Study
  • Corona passport: Not recommended but may be unavoidable, says WHO
  • 23-year-old MBBS student dies of COVID after the first dose of vaccination
  • SARS-CoV-2 evolved naturally and it’s far more widespread than previously believed
  • ‘Get COVID-19 vaccination 24*7’: Government removes time cap

Health Calculators

BMI Calculator
bmi Calculator
Ideal Body Weight
ideal body weight
Daily Calorie Intake
Daily calorie intake
Calories Burned
calories burned

Related Stories

COVID-19 antibodies, vaccines less effective against coronavirus variants: Study

COVID-19 antibodies, vaccines less effective against coronavirus variants: Study

Corona passport: Not recommended but may be unavoidable, says WHO

Corona passport: Not recommended but may be unavoidable, says WHO

SARS-CoV-2 evolved naturally and it’s far more widespread than previously believed

SARS-CoV-2 evolved naturally and it’s far more widespread than previously believed

‘Get COVID-19 vaccination 24*7’: Government removes time cap

‘Get COVID-19 vaccination 24*7’: Government removes time cap

23-year-old MBBS student dies of COVID after the first dose of vaccination

23-year-old MBBS student dies of COVID after the first dose of vaccination

Health News in Hindi

Jujube Health Benefits: कैल्शियम की कमी वाले लोग गर्मियों में खाएं बेर, इन रोगों को दूर करने में भी मिलेगा फायदा

कैटरीना कैफ ने फिल्‍म “Tiger 3” के लिए ली है 14 दिनों की स्‍पेशल स्‍टंट ट्रनिंग, दक्षिण कोरियाई टीम ने किया ट्रेंड

आयुर्वेद के मुताबिक कैसा होना चाहिए मधुमेह में आपका खानपान? एक्सपर्ट से सीखें ब्लड शुगर कंट्रोल करने के परफेक्ट टिप्स

West Bengal COVID-19 vaccine: पश्चिम बंगाल में सिर्फ इन 5 प्राइवेट अस्‍पतालों में लग रही है वैक्‍सीन, जानिए अपने इलाके का अस्‍पताल

Covaxin और Covishield लगने के बाद कितने दिन में असर करती हैं? जानिए पूरी जानकारी

Read All

Recent Posts

  • Colorectal cancer can be cured if detected early: New AI device can detect the disease accurately
  • COVID-19 antibodies, vaccines less effective against coronavirus variants: Study
  • Beware: Accumulation of belly fat as you approach menopause can up your heart disease risk
  • Bollywood celebrities who gave up meat and turned vegetarian
  • Corona passport: Not recommended but may be unavoidable, says WHO

About The health Site

TheHealthSite.com is India's largest health site with more than 40 lakh unique visitors per month. We focus on fitness, beauty, health, pregnancy and more.

Most popular health and wellness website in India in 2012 at the Website of the year awards.

health@corp.india.com
+91 – 22 – 6697 1234
Landline Phone number 91 – 22 – 2490 0302.

ZEE ENTERTAINMENT ENTERPRISES LTD, 18th floor, A-Wing, Marathon Futurex, N. M. Joshi Marg, Lower Parel, Mumbai, Maharashtra 400013.

Useful Links

  • Weight Loss
  • Keto Diet Tips
  • Skin Care Tips
  • Intermittent Fasting
  • Apple Cider Vinegar
  • Ashwagandha
  • Cancer
  • Pneumonia
  • Diarrhoea
  • Dengue
  • Typhoid
  • Tuberculosis
  • Chickenpox
  • Chikungunya
  • Depression
  • Hepatitis
  • Diabetes
  • Type 2 diabetes
  • Arthritis
  • Swine Flu
  • Baby Names
  • Cough and cold
  • Heart Attack
  • Breast Cancer
  • Ebola Virus
  • Dengue
  • Malaria
  • International Yoga Day
  • Hypotension
  • Heart Failure
  • Asthma
  • Brain Tumour
  • Celebrity Fitness
  • Goitre
  • HIV/AIDS

We respect your privacy

  • Disclaimer
  • Privacy Policy
  • Contact Us
  • Author Profiles

Copyright © 2021 Zee Entertainment Enterprises Limited. All rights reserved.